Publié le March 30, 2023
Abstract: Purpose Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts…
Lire la suite
Publié le December 12, 2022
Randomized controlled trials (RCTs), particularly in phase 3, are the preferred sources of evidence for drug approval and reimbursement decisions….
Lire la suite
Publié le June 29, 2022
Generalized Pairwise Comparisons – GPC Today’s session is focusing on an innovative statistical methodology called Generalized Pairwise Comparisons – or…
Lire la suite
Publié le February 21, 2022
Phase I/II study in cancer patients showcases eClinical effectiveness. An Article written by IDDI Published in Applied Clinical Trials, February…
Lire la suite
Publié le January 4, 2022
Join IDDI experts to get updated on efficacy assessment in early-phase trials and more! THURSDAY, FEBRUARY 3 – 9:00 –…
Lire la suite
Publié le November 10, 2021
Be updated on different types of Bayesian and frequentist designs that may be used for expansion cohorts in phase 1…
Lire la suite
Publié le November 3, 2021
This webinar was presented by Laurence Collette, MSc, PhD, Principal Statistician, Consulting Services at IDDI at the 5th Annual Next…
Lire la suite
Publié le October 5, 2021
Demystifying different types of Bayesian and frequentist designs that may be used for first-in-human or other types of phase I…
Lire la suite
Publié le September 15, 2021
Using the promising-zone approach can salvage an underpowered trial. Sample size Re-estimation (SSRE) is a relatively new concept, but, thanks…
Lire la suite
Publié le September 2, 2021
Vaiva Deltuvaite-Thomas, Research Statistician, IDDI and Prof. Tomasz Burzykowski, VP Research IDDI have just published an article on operational characteristics…
Lire la suite